Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Novartis petitions Supreme Court in effort to 'vigorously defend' Gilenya patent
Endpoints
Tue, 01/24/23 - 06:18 pm
Novartis
Supreme Court
Gilenya
patents
generics
multiple sclerosis
MS
Novartis CEO says Covid likely to become endemic, urges investment in pandemic preparedness
CNBC
Fri, 01/20/23 - 10:32 am
Novartis
Pharma CEOs
Vas Narasimhan
COVID-19
pandemic
Public Health
A year of two halves for US approvals
EP Vantage
Thu, 01/19/23 - 09:38 am
FDA
drug approvals
Mounjaro
Eli Lilly
Vabysmo
Roche
Opdualag
Bristol Myers Squibb
Carvykti
JNJ
Vtama
Roivant
Pluvicto
Novartis
AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out
Fierce Pharma
Wed, 01/18/23 - 10:53 pm
AbbVie
Novartis
China
drug pricing
Pfizer
Paxlovid
EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma
BioPharma Dive
Tue, 01/17/23 - 10:26 am
Novartis
gene therapy
Zolgensma
SMA
Europe
JPM23: After rock climbing in biotech, Novartis' CMO is back to support hopeful hike to US summit
Fierce Biotech
Thu, 01/12/23 - 10:36 am
Novartis
JPMHC 2023
Dicerna Pharmaceuticals
Axcella Health
JPM Day 1: Highlights
BioSpace
Mon, 01/9/23 - 11:01 pm
JPMHC 2023
Sarepta Therapeutics
Biomarin
Alnylam
JNJ
Arrowhead Pharmaceuticals
Novartis
Bristol Myers Squibb
JPM23: Is Novartis weighing respiratory, eye drug sell-offs after Sandoz? Not necessarily, CEO says
Fierce Pharma
Mon, 01/9/23 - 10:43 pm
Novartis
JPMHC 2023
Sandoz
Respiratory
eye health
Novartis to pay $245 mln to end antitrust cases over Exforge drug generics
Reuters
Thu, 01/5/23 - 09:57 am
Novartis
generics
antitrust
legal
Exforge
hypertension
The biggest-selling pharma companies of 2023
EP Vantage
Wed, 01/4/23 - 05:20 pm
Pfizer
Merck
JNJ
Novartis
AbbVie
Roche
Novartis to cut 280+ jobs in New Jersey
Endpoints
Mon, 12/19/22 - 10:21 pm
Novartis
layoffs
New Jersey
AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in
Fierce Biotech
Fri, 12/16/22 - 10:47 am
AstraZeneca
Alexion
PNH
Ultomiris
Soliris
Roche
Apellis
Novartis
Novartis sells U.S. rights to five drugs to Harrow for up to $175M
Medical Marketing and Media
Wed, 12/14/22 - 07:43 pm
Novartis
eye health
restructuring
Harrow Health
ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options
Fierce Biotech
Tue, 12/13/22 - 10:36 am
Novartis
ASH 2022
CAR-T
T-Charge
ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca
Fierce Biotech
Tue, 12/13/22 - 10:28 am
ASH 2022
Novartis
iptacopan
AstraZeneca
Clovis files for bankruptcy, will keep operating and plans to sell pipeline asset to Novartis
Endpoints
Mon, 12/12/22 - 10:14 am
Clovis Oncology
bankruptcy
Novartis
Novartis' iptacopan meets PhIII test in fight against rare blood disease
Endpoints
Thu, 12/8/22 - 10:37 am
Novartis
clinical trials
paroxysmal nocturnal hemoglobinuria
iptacopan
Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial
BioSpace
Wed, 12/7/22 - 11:39 pm
Novartis
Kisqali
breast cancer
clinical trials
In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise
BioSpace
Mon, 12/5/22 - 10:58 am
Novartis
prostate cancer
Pluvicto
clinical trials
patents
patent cliff
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
Pages
« first
‹ previous
…
6
7
8
9
10
11
12
13
14
…
next ›
last »